BeiGene Ltd.
- Country
- 🇨🇳China
- Ownership
- Public
- Established
- 2010-01-01
- Employees
- 10K
- Market Cap
- $22.1B
- Website
- http://www.beigene.com
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
- First Posted Date
- 2017-12-02
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 805
- Registration Number
- NCT03358875
- Locations
- 🇵🇱
Centrum Onkologii Instytut Im M Sklodowskiej Curie, Warszawa, Poland
🇹🇷Iu C, Clinical Research Excellence Application and Research Center, Stanbul, Turkey
🇧🇷Hospital Sao Lucas Da Pucrs, Porto Alegre, Brazil
A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL
- Conditions
- Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2017-11-08
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 590
- Registration Number
- NCT03336333
- Locations
- 🇺🇸
Augusta University, Augusta, Georgia, United States
🇺🇸Northwestern University, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Study of the Efficacy, Safety and Pharmacokinetics of Pamiparib (BGB-290) in Participants With Advanced Solid Tumors
- Conditions
- Advanced High-grade Ovarian CancerTriple Negative Breast Cancer
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2025-02-04
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 128
- Registration Number
- NCT03333915
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Henan Cancer Hospital, Zhengzhou, Henan, China
Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 44
- Registration Number
- NCT03332173
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma
- Conditions
- Relapsed/Refractory Follicular Non-Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2017-11-06
- Last Posted Date
- 2025-01-23
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 217
- Registration Number
- NCT03332017
- Locations
- 🇧🇬
University Multiprofile Hospital For Active Treatment Dr Georgi Stranski, Pleven, Bulgaria
🇧🇬Acibadem City Clinic Mhat Tokuda Ead, Sofia, Bulgaria
🇧🇬University Multiprofile Hospital For Active Treatment Saint Ivan Rilski, Sofia, Bulgaria
Phase 1 Study to Investigate Effect of Rifampin and Itraconazole on the Pharmacokinetics of BGB-3111 in Healthy Subjects
- Conditions
- Healthy Volunteers: Asian, Non-Asian
- Interventions
- First Posted Date
- 2017-10-04
- Last Posted Date
- 2019-11-01
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 40
- Registration Number
- NCT03301181
- Locations
- 🇺🇸
West Coast Clinical Trials (WCCT), Cypress, California, United States
A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
- First Posted Date
- 2017-07-06
- Last Posted Date
- 2025-02-05
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 70
- Registration Number
- NCT03209973
- Locations
- 🇨🇳
West China Hospital, Sichuan University, Chengdu, Sichuan, China
🇨🇳Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin, China
🇨🇳Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)
- Conditions
- Refractory Mantle Cell LymphomaRelapsed Mantle Cell Lymphoma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 86
- Registration Number
- NCT03206970
- Locations
- 🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳The First Hospital of Jilin University, Changchun, Jilin, China
Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Conditions
- Relapsed or Refractory Chronic Lymphocytic LeukemiaRelapsed or Refractory Small Lymphocytic Lymphoma
- Interventions
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 91
- Registration Number
- NCT03206918
- Locations
- 🇨🇳
Peking University Peoples Hospital, Beijing, Beijing, China
🇨🇳Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
A Study to Investigate Zanubrutinib in Chinese Participants With B-cell Lymphoma
- First Posted Date
- 2017-06-16
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- BeiGene
- Target Recruit Count
- 44
- Registration Number
- NCT03189524
- Locations
- 🇨🇳
Tongji Hospital of Tongji Medical College Huazhong University of Science and Technology, Wuhan, Hubei, China
🇨🇳Institute of Hematology and Hospital of Blood Disease, Tianjin, Tianjin, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China